About the Institute
Located on the main campus of Utah State University, the Institute for Antiviral Research is comprised of a team of recognized scientists working to identify antiviral agents and vaccines against a wide range of human pathogenic viruses. Six principal investigators collaborate at the IAR with expertise in respiratory, hemorrhagic fever, and neuroinvasive viruses.
Since being founded in 1978, the IAR and its researchers have been effectively involved in the pre-clinical development of several FDA-approved antiviral compounds in the past, including ribavirin (Virazole™), ganciclovir (Cytovene™), stavudine (Zerit™), and oseltamivir (Tamiflu™), as well as T-705 (favipiravir) which is approved for clinical use in Japan and being evaluated currently in the U.S. Researchers at the IAR completed studies evaluating the in vitro and in vivo efficacy to support FDA approval.
In addition to receiving funding from the National Institute of Health, the National Institute of Mental Health, and the Department of Defense, the IAR also performs fee-for-service testing for private pharmaceutical and research companies. We have numerous in vitro and in vivo models of viral disease that we have established over the past 40 years.
2019 Novel Coronavirus
We have the 2019 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) which is validated for in vitro testing. An animal model for SARS-CoV-2 is being developed now and will be available soon. Check the In Vitro Testing or In Vivo Testing for more information or contact us to request a quote or additional information.